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Abstract
Background:  Campylobacter  infection is a major cause of bacterial gastrointestinal disease.
Exposure to Campylobacter is known to produce an immune response in humans that can prevent
future symptomatic infections. Further, studies of the general population have shown that
seroprevalence to Campylobacter increases with age.
Methods: A large collection of serotyped Campylobacter isolates, obtained from human clinical
faecal samples, were analysed by comparing the ratio of uncommon to common serotypes by
different age groups, using χ2 tests.
Results: We have identified that older age groups, as well as having generally lower incidence, are
significantly less likely to be infected by the more common serotypes.
Conclusion: These results are indicative of acquired immunity, however, further studies are
needed to rule out the confounding effects of the variations in exposure pathways experienced by
different age groups.
Background
Campylobacter is the greatest cause of human bacterial gas-
troenteritis in the developed world [1], with more than
50,000 cases reported in the UK alone each year [2]. How-
ever, due to under-reporting, it is believed that the true
number of cases is around eight times this [2], suggesting
humans are infected on average at least once during their
lifetime. Symptoms of campylobacteriosis include fever,
abdominal cramp, and bloody diarrhoea, which can last
for approximately seven days after infection, with one in
a 1000 cases leading to the more serious neurological dis-
ease, Guillain-Barré syndrome [3].
Approximately 90% of Campylobacter  infections are C.
jejuni, while the remainder are predominantly C. coli [4].
A variety of typing techniques have been used to subtype
these species, including phenotypic Penner heat stable
antigen serotyping, genotypic PFGE, AFLP and MLST,
which have demonstrated high variability in the genome.
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Human seroprevalence studies of C. jejuni specific anti-
gens have shown that IgG, IgM, and IgA antibodies are
produced during infection [5,6]. The IgM and IgA anti-
body levels quickly decrease after infection, however, the
IgG antibodies can remain elevated for months or years
afterwards [5]. A recent study of seroprevalence in Danish
adults looked at IgG antibodies in a sample of 1112 peo-
ple from Copenhagen [7]. It was found that the percent-
age of people with C.jejuni-specific IgG antibodies
increased with age, from 20.6% in the 15–34 years age
group to 32.4% in the 50 – 69 years age group.
Humans are likely to be exposed to Campylobacter  a
number of times during their lifetime, resulting in
immune responses that can last several years [8]. Further,
as the types/strains of Campylobacter are diverse, it is prob-
able that people are more likely to develop immune pro-
tection to the more common types to which they are
exposed. Hence we hypothesise that the general popula-
tion develops increased immunity to the more common
types of Campylobacter as they grow older. Here we test this
hypothesis by analysing a large dataset of Penner sero-
typed cases of human campylobacteriosis, stratified by
age, to determine if the prevalence of common serotypes
decreases with the age of the population.
Methods
Data were collated from the Grampian NHS trust report-
ing human infections of C. jejuni in Grampian, Scotland
(approximately 2300 cases during 1997 – 1999). These
data included each patient's age, gender and date of infec-
tion. Isolate serotyping had been performed on these
cases, using the Penner method [9]. Cases with no
recorded age (105), as well as untyped and C. coli cases
(168), were omitted from the data set, leaving 1955 typed
cases of C. jejuni.
The C. jejuni cases were separated into 48 Penner sero-
types, which were then collected together into recognised
groupings, such as HS:1,44, HS:6,7, and HS:4 complex
(comprising serotypes HS:4, 13, 16, 43, 50) [10]. The
prevalence of each serotype was determined, with sero-
types accounting for more than 10% of the cases being
defined as common, and those accounting for less than
10% being classed as uncommon. These data were strati-
fied by age (five year age groups), then ratios of uncom-
mon to common types were determined. The incidence
(cases per 100,000) of each age group was calculated,
using the population data from the 2001 Scottish Census
[11]. Finally χ2 tests were used to test the statistical signif-
icance of differences between age group ratios.
Results
The overall incidence of Campylobacter infection by five-
year age groups (Figure 1A) shows a large number of cases
in the 0–4 years age group (241 cases per 100,000). There
is a drop off, before a second peak found in the 25–29
years age group (205 cases per 100,000). From 30 years of
age onwards there is a gradual reduction in cases down to
the minimum of less than 60 cases per 100,000 among
the patients 75 years and older.
The most prevalent Penner serotypes found in these data
were HS:4 complex, HS:2, and HS:1,44 (427, 420, and
205 cases respectively) which account for a total of 53.8%
of all tested cases (Table 1). These three type groups were
classified as common, for comparison against the 40
other uncommon serotypes.
The ratios of uncommon to common types by five-year
age groups (Figure 1B) show that for ages 0 – 39 there is a
consistently greater number of infections from the com-
mon types (HS:4 complex, HS:2, HS:1,44), with an
uncommon/common mean ratio of 0.71 (± 0.10). For
patients aged 40 years and older, all age groups but one
(45–49 years) have a higher incidence of uncommon
types (mean: 1.20 ± 0.18). A χ2 test confirms that the dif-
ference is highly statistically significant (p < 0.001).
Discussion
In this study we compiled the Penner serotype data for
nearly 2000 cases of human Campylobacter jejuni infec-
tions in Grampian, Scotland, determined which were the
common types, and identified that these types are signifi-
cantly more prevalent in younger age groups (less than
approximately 40 years). The reduced frequency of com-
mon types in older age groups, along with a general reduc-
tion in incidence of infection, provides evidence for the
hypothesis that people develop immunity to the most
common types of C. jejuni during their lifetimes.
From the age-specific incidence data (Figure 1A) it is clear
that the highest incidence occurs in the 0–4 years age
group, which agrees with previous studies [12]. This could
be due to many factors including lack of immunity, higher
rates of reporting in the age group, or a higher risk of expo-
sure to a particular infection pathway. For example, in
rural regions such as Grampian, Scotland, where farm ani-
mals shed high loads into the environment, small chil-
dren may have a high likelihood of coming into contact
with, and ingesting, the bacteria. The reduction of inci-
dence in the 5–9 and again in the 10–14 age groups is sim-
ilar to previous studies [13], which may be due to
improved hygiene reducing the risk of environmental
exposure. This trend then reverses with a sharp increase in
incidence in the older teens/early twenties. This occurs
around the age when people are more likely to be travel-
ling and hence coming into contact with new strains.
Case-control studies have found that international and
national travel is an important risk factor for infectionBMC Infectious Diseases 2005, 5:66 http://www.biomedcentral.com/1471-2334/5/66
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C. jejuni incidence and ratio of uncommon to common serotypes Figure 1
C. jejuni incidence and ratio of uncommon to common serotypes. Human campylobacteriosis in Grampian Scotland 
(1997–1999). a) Incidence of reported cases and b) Ratio of uncommon to common serotypes.BMC Infectious Diseases 2005, 5:66 http://www.biomedcentral.com/1471-2334/5/66
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[14]. In humans >30 years, a gradual reduction in inci-
dence is observed. This, taken together with the results of
the Danish study [7] showing that seroprevalence
increases with age, and the fact that it has been demon-
strated that elevated levels of Campylobacter jejuni immu-
noglobulin A reduces the risk of Campylobacter diarrhoea
in adults traveling to Thailand [15], suggests that immu-
nity may be causing protection from Campylobacter infec-
tion, or at least symptomatic infection. However, the
lower incidence could also be caused by reduced exposure
to the infection pathways more common in younger age
groups.
The common serotypes found in these data (Table 1) are
consistent with those found in previous studies [16,17],
which are also the same types found in poultry and farm
animals [17]. Although we do not have the epidemiolog-
ical data to ascertain whether the human cases can be
attributed to animals/poultry it is clear that the majority
of cases in all age groups below 40 are from these com-
mon serotypes (Figure 1B).
Conclusion
These data presented here demonstrate lower incidence
along with the reduced occurrence of infection from the
common serotypes with age, supporting the hypothesis of
increased immunoprotection in the population with age.
However, it is possible that changing exposure to Campy-
olobacter with age would confound our results, which can
only be clarified by performing a comprehensive epidemi-
ological age-stratified exposure assessment.
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